Emergent BioSolutions

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives, Antibody Therapeutics, Devices, and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Emergent BioSolutions addresses revenue challenges, eyes market expansion opportunities

Emergent BioSolutions navigated revenue challenges in Q4 2022, focusing on core businesses and strategic initiatives with a strong financial outlook for 2023.
The company faces competition and market positioning challenges in the OTC space for NARCAN, while opportunities exist in market expansion and government contracts.
Balancing pricing strategies, securing procurement decisions, and extending credit facility maturity are key focus areas for sustained growth and profitability.
Overall, Emergent BioSolutions demonstrates resilience and adaptability in addressing market challenges while capitalizing on opportunities for growth and market expansion.

Emergent BioSolutions (EBS) excels in Q1 with FDA approvals and strategic sales

Emergent BioSolutions (EBS) delivered a robust Q1 performance with notable achievements in FDA approvals and strategic business decisions. While facing challenges in gross margin changes and insurance coverage discussions, EBS remains focused on growth opportunities and product innovation.

Emergent BioSolutions reports Q2 growth, shifts focus to core products

Emergent BioSolutions' Q2 2023 earnings call highlighted positive financial results, strong NARCAN Nasal Spray sales, and strategic shifts towards core products. The company provided updated guidance for 2023, focusing on revenue expectations and cost-saving measures. Analyst questions centered on revenue breakdown, restructuring efforts, and future growth prospects.

Emergent BioSolutions (EBS) exceeds Q3 expectations, focuses on growth

Emergent BioSolutions (EBS) demonstrated strong financial performance in Q3 2023, exceeding revenue and EBITDA expectations. The company's focus on core products, compliance, and cost reduction initiatives positions it well for future growth. Challenges include a rescheduled earnings release and the need to meet growing demand for NARCAN Nasal Spray.

Emergent BioSolutions reports solid Q4 performance and outlines growth strategies

Emergent BioSolutions showcased strong financial performance and operational progress in Q4 2023, setting the stage for a promising 2024.
The company's strategic focus on debt reduction, quality enhancement, and core product strength bodes well for future growth.
While challenges persist in managing product sales variability and addressing stakeholder inquiries, opportunities for expansion and success are abundant.

Emergent BioSolutions excels in Q1, raises 2024 outlook amid growth prospects

Emergent BioSolutions reported strong Q1 performance, raised profit outlook for 2024, and highlighted growth drivers for key products. The company's strategic actions to reduce costs, improve profitability, and focus on core businesses demonstrate a proactive approach to driving long-term value. Despite challenges like potential generic competition, EBS remains well-positioned to leverage growth opportunities and sustain its positive momentum.

Emergent BioSolutions (EBS) exceeds Q2 guidance, poised for growth

Emergent BioSolutions (EBS) delivered strong Q2 results, exceeding revenue guidance and showcasing operational improvements.
The company's strategic actions, product highlights, and financial performance position it well for future growth and value creation.
Challenges in revenue sustainability and operational changes exist, but opportunities in international expansion, partnerships, and innovation are key drivers.
Overall, Emergent's focus on public health preparedness, opioid crisis solutions, and strategic growth initiatives bode well for its long-term success.

Emergent BioSolutions excels in Q3, poised for growth opportunities

Emergent BioSolutions delivered a strong Q3 performance, showcasing financial resilience, operational excellence, and strategic advancements across key business segments.
While facing challenges in pricing dynamics and revenue mix, the company's focus on growth opportunities, compliance, and leadership appointments positions them for sustained success.
With a solid financial foundation, improved guidance, and a strategic roadmap for growth, Emergent is well-equipped to navigate challenges, capitalize on opportunities, and drive shareholder value.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ACADIA Pharma

While the theme underperformed considerably in 2021, declining by 31%, it has gained about 2% year-to-date in 2022, outperforming the S&P 500, which remains down by about 9%.

These Healthcare Stocks Took A Beating Through Covid. Will They Outperform In 2022?

Aerie Pharmaceuticals

Editas Medicine

Moderna

Vir Biotechnology

Let us take a look at five biotech/drug companies, namely, MRNA, EDIT, VIR, EBS and AERI, which are due to release their quarterly results on Feb 24.

Drug/Biotech Stocks' Q4 Earnings on Feb 24: MRNA, EBS & More

Emergent BioSolutions has been an exiled ticker following the vaccine mix-up at the company's Bayview Facility last year. Although the company has addressed the issues in Bayview, it looks as if the market has expelled EBS as a good investment at this point in time.

Emergent BioSolutions: Still A Bargain Regardless Of Diminished Growth Forecasts

GAITHERSBURG, Md., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 24, 2022 at 5:00 pm eastern time to discuss the financial results for the fourth quarter 2021, recent business developments, financial outlook for full year 2022, and revenue guidance for the first quarter of 2022.

Emergent BioSolutions to Release Fourth Quarter 2021 Financial Results and Conduct Conference Call on February 24, 2022

Cavco Industries

Ingevity

TechTarget

The S&P 500 saw the trailing 12-month real earnings per share of its member companies increase by a compound annual growth rate of 11.6% over the past five years. The index, which stood at a price of $4,500.53 per share as of Friday, has climbed more than 95% over the past five years.

4 Companies Growing Earnings Fast

Fuad El-Hibri to Retire After More Than 20 Years Fuad El-Hibri to Retire After More Than 20 Years

Founder and Executive Chairman of Emergent BioSolutions Announces Retirement

GAITHERSBURG, Md., Jan. 09, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced its financial guidance for 2022 and selected preliminary unaudited financial results for 2021.

Emergent BioSolutions Announces 2022 Financial Guidance, Provides Preliminary 2021 Results

Emergent (EBS) initiates a phase I study evaluating EBS-UFV-001, the company's investigational universal influenza vaccine candidate.

Emergent (EBS) Begins Dosing in Study on Influenza Vaccine

Emergent BioSolutions Inc. EBS, +3.55% said Thursday that it began dosing participants in a Phase 1 clinical trial for its universal influenza vaccine candidate. The randomized, double-blind, placebo-controlled dose-escalation study is being conducted in Australia; 60 healthy adults will be enrolled in the study.

Emergent begins clinical trial for universal flu vaccine candidate

GAITHERSBURG, Md., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the first participant dosed in its phase 1 study, EBS-UFV-001, evaluating the safety, tolerability, and immunogenicity of the company's investigational universal influenza vaccine candidate. This current version of Emergent's universal influenza vaccine candidate contains multiple components intended to induce broad and supra-seasonal immunity against influenza A viruses.

Emergent BioSolutions Announces Initiation of Phase 1 Study Evaluating Its Universal Influenza Vaccine Candidate

SiTime Corporation

Domtar

NEW YORK, Nov. 22, 2021 /PRNewswire/ -- SiTime Corp. (NASD: SITM) will replace Emergent BioSolutions Inc. (NYSE: EBS) in the S&P MidCap 400, and Emergent BioSolutions will replace Domtar Corp. (NYSE: UFS) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, November 30. Paper Excellence B.V.

SiTime Set to Join S&P MidCap 400; Emergent BioSolutions to Join S&P SmallCap 600

The modification/loss of a contract coupled with a weak earnings report sent the stock tumbling 40%.

Emergent BioSolutions: Rapid-Return Trade With More Legs

The company has given 250 million reasons why investors should buy its stock.

Why Emergent BioSolutions Popped by Over 4% Today

After a fiasco surrounding the contamination of COVID-19 vaccine doses in its facilities, Emergent BioSolutions Inc's (NYSE: EBS) manufacturing deal with the US government has come to an end. CEO Bob Kramer said that the two parties "mutually agreed" to terminate the contract, evaporating about $180 million in deal value.

See Why Emergent BioSolutions Stock Plunged 37% On Friday?

The U.S. government canceled a contract related to pandemic preparation.

Why Emergent Biosolutions Stock Is Crashing Today

Emergent's (EBS) third-quarter 2021 earnings and sales miss estimates. The company tightens the revenue guidance on lower anticipated revenues from the CDMO segment.

Emergent (EBS) Q3 Earnings Miss, Contract Revenue View Down

Emergent Biosolutions shares plunged after the Covid vaccine maker and federal government “mutually agreed” to cancel its multimillion-dollar contract.

Emergent Biosolutions shares plunge by more than 37% after U.S. cancels deal with Covid vaccine maker

Shares of Emergent BioSolutions Inc tumbled 15% on Friday, following the termination of a U.S. government contract to reserve capacity and expand manufacturing of third-party COVID-19 vaccines at its sites.

Emergent slumps as U.S. terminates COVID-19 vaccine manufacturing deal

Shares of Emergent Biosolutions Inc. [s:ebs] dropped 14% in premarket trading after the company disclosed that the U.S. government had cancelled a contract with the vaccine manufacturer. Emergent's Baltimore facilities were found in March to have contaminated millions of Johnson & Johnson COVID vaccines, causing production delays that lasted months.

Emergent Biosolutions shares tumble on news it will lose COVID vaccine production contract with govt'

The company came under intense scrutiny in April following reports of a production error at its plant manufacturing Covid-19 vaccines.

Emergent BioSolutions Stock Plunges After Key Government Contract Terminated

Emergent BioSolutions Inc. (EBS) CEO Bob Kramer on Q3 2021 Results - Earnings Call Transcript

Emergent Biosolutions (EBS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Emergent Biosolutions (EBS) Q3 Earnings Expected to Decline

GAITHERSBURG, Md., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, November 4, 2021 at 5:00 pm eastern time to discuss the financial results for the third quarter of 2021, recent business developments, and financial outlook for full year 2021.

Emergent BioSolutions to Release Third Quarter 2021 Financial Results and Conduct a Conference Call on November 4, 2021

GAITHERSBURG, Md., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the first participant dosed in its pivotal phase 3 study evaluating the safety and immunogenicity of the company's investigational chikungunya virus (CHIKV) virus-like particle (VLP) vaccine candidate, CHIKV VLP, in a single dose. CHIKV VLP is the only VLP-based vaccine currently in clinical development for active immunization against chikungunya disease.

Emergent BioSolutions Announces Initiation of Pivotal Phase 3 Study Evaluating the Safety and Immunogenicity of Its Single-Dose Chikungunya Vaccine Candidate, CHIKV VLP

The stock price of Emergent Biosolutions, a specialty biopharmaceutical company, has seen a fall of 15% over the last twenty-one trading days, while it is down 42% year-t0-date. EBS stock has had a tough year so far, with its manufacturing unit in Baltimore facing the heat after contamination of.

News for Emergent BioSolutions Stock (EBS)